HIGHLIGHTS

  • The Alberta Securities Commission dismissed Curaleaf's application challenging Aurora's at-the-market Equity programme, which Aurora says confirms that the programme complies with securities law.
  • Aurora says it announced the programme in February, more than six months before Curaleaf launched its hostile bid, and that its last sale under it was in August.
  • Aurora's board unanimously urges shareholders to take no action on Curaleaf's revised offer and to withdraw any shares already tendered.

Aurora Cannabis Inc. (TSX:ACB) announced before the market opened on Monday, October twenty-sixth, that the Alberta Securities Commission had dismissed an application by Curaleaf seeking to halt the company's at-the-market equity programme. Aurora said the decision, which it described as a ruling in its favour, confirms that the programme complies with securities law. The announcement from Edmonton adds a legal chapter to the hostile Takeover contest that Curaleaf has been pursuing, and it came as Aurora's board repeated its advice that shareholders take no action on the revised offer.

What the Commission Decided and What the Release Does Not Say

An at-the-market programme allows a company to issue new shares gradually into the trading market at prevailing prices, usually through an agent, instead of raising money in a single underwritten offering. Curaleaf asked the Alberta regulator to stop Aurora from using the programme during the bid. The commission, one of the provincial members of the Canadian Securities Administrators, dismissed the application. The release summarises the outcome as it sees it and does not set out the commission's reasoning, so the detailed grounds are not part of the information available here.

Aurora stressed the sequence of events. It publicly announced the programme in February, more than six months before Curaleaf launched its hostile bid, and said the purpose was flexibility to pursue accretive and strategic opportunities, such as added cultivation capacity and acquisitions. The company said its last sale under the programme took place on August eighteenth and that it has not used the programme at any point during the hostile bid. Those statements are Aurora's own account and form the core of its argument that the application lacked merit.

Curaleaf's Revised Offer as Described in Public Filings

According to a Curaleaf release, the revised offer carries an implied value of five dollars per Aurora share, made up of zero point four zero one three of a Curaleaf subordinate voting share plus one dollar in cash. The cap on the maximum value per share was reportedly raised from five dollars to six dollars. Curaleaf describes this as an eighty-six per cent premium to Aurora's unaffected thirty-day volume-weighted average price of two dollars and seventy-five cents. Because part of the offer is paid in Curaleaf shares, its value to Aurora shareholders moves with Curaleaf's trading price, and the reported cap limits the maximum value per share.

The report also says the offer's expiry was extended from December first to December fourth at eleven fifty-nine in the evening, Mountain time. In its statement of October nineteenth, Curaleaf, which trades on the Toronto exchange as (TSX:CURA), challenged Aurora's rejection of the proposal. It cited an implied multiple of fourteen point three times Aurora's adjusted Earnings before interest, taxes, Depreciation and amortization for the current year. Curaleaf also alleged that Aurora sold shares under the programme at prices as low as two dollars and sixty cents in July and had blocked due diligence. Those are Curaleaf's allegations, and Aurora's release disputes the premise of the application.

Challenges of this kind reflect a long-standing concern in Canadian securities regulation. Regulators have historically scrutinised steps by a target company that could reduce the ability of shareholders to respond to a bid, including share issuances during an offer period. That background helps explain why a bidder might ask a commission to stop an equity programme. Aurora's position is that its programme predates the bid, was publicly announced and has not been used since August, while Curaleaf's filings frame the issue differently.

The Board's Position and the Defence Process

Aurora's board unanimously urges shareholders to take no action and not to tender to the offer, and it asks anyone who has already tendered to withdraw. Executive Chairman and Chief Executive Officer Miguel Martin said the unsuccessful application distracts from what he sees as fundamental shortcomings in Curaleaf's revised bid. Kingsdale Advisors serves as the Shareholder information agent.

In a Canadian takeover bid, the bidder makes its offer directly to shareholders, who decide individually whether to tender, and the target's board must respond through a directors' circular. A bid is also subject to conditions, including a minimum level of tendered shares, and it must stay open for a minimum period set by securities rules. That framework explains why both companies are issuing frequent updates, since each filing is intended to shape the decisions of shareholders before the offer expires. Aurora added that its strategic alternatives process is ongoing.

The Medical Cannabis Business at the Centre of the Dispute

Aurora describes itself as a global medical cannabis company serving Canada, Europe, Australia and New Zealand, with facilities certified to good Manufacturing practice standards in Canada and Germany. Its medical focus and its European presence distinguish it from many domestic producers that depend mainly on adult-use sales. Readers following Canadian cannabis stocks will recognise that the sector has been shaped by consolidation, provincial distribution rules and Health Canada licensing, and a takeover contest of this kind brings those themes into sharp focus.

Aurora's shares are listed on both the Toronto exchange and the Nasdaq market under the same symbol, which means the bid and the programme draw scrutiny from regulators and investors on both sides of the border. The strategic alternatives process that the board has described is a standard defensive step in Canadian takeover contests, in which a target examines whether other transactions or standalone plans might offer shareholders better outcomes. Aurora has not disclosed in this release what that process has produced so far.

What to Watch as the Offer Period Runs

The ruling removes one legal question but not the central one, which is how Aurora's shareholders respond to a revised offer that the board opposes. Curaleaf has the option of further revisions, and Aurora's board has indicated that its alternatives process is continuing.

For readers following the story, the next markers are the offer expiry date, any further statements from either board and any appeal or follow-up proceedings. Takeover contests can change quickly, and a regulator's decision on one procedural point does not determine the outcome of the bid itself.